DnaJ heat shock protein family (Hsp40) member C18Genealiases: []
Q-omics provides the consensus-scored DNAJC18 profile across patient tissues and cancer cell-line models. DNAJC18 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, DNAJC18 is differentially expressed in 14, with the highest sampling consensus in LUSC. Additionally, DNAJC18 RNA expression shows 23,607 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, LUSC, and GBM as cancer lineages where DNAJC18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJC18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJC18 survival associations across molecular data types. DNAJC18 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJC18 RNA expression–survival associations across cancer types. High DNAJC18 expression shows unfavorable associations in KICH, LUSC and DLBC, but favorable associations in KIRC, BRCA and LGG. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for DNAJC18 RNA expression.
This table summarizes DNAJC18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for DNAJC18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJC18 shows lower tumor expression in LUSC, BLCA, KICH, UCEC and LUAD and higher tumor expression in LIHC. The LUSC box plot shows higher DNAJC18 RNA expression in normal versus tumor tissue (log2 FC = −1.292, t-test p < 0.001).
This table shows molecular features associated with DNAJC18 in patient tissues and cancer cell lines. In patient samples, DNAJC18 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAJC18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LUNG_NSCLC_LUAD.
